Track market-moving stories before they get noisy

Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

FDA PDUFA Goal Date Set for Dec. 27, 2026

, /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. Acute pain affects more than 80 million individuals in the United States each year, where opioids remain a commonly used treatment option.1,2

"FDA's acceptance of the New Drug Application for investigational fast-acting meloxicam takes us one step closer to bringing a potential non-opioid first-line treatment option to patients with moderate-to-severe acute pain, which will help address an important public health need in the United States," said Philippe Martin, Viatris Chief R&D Officer. "Fast-acting meloxicam is one of several value-added medicines in our pipeline. We are proud of the strength of the clinical profile supporting this program, which includes a fast speed of onset of action, strong and sustained analgesic efficacy with a significant reduction in opioid usage, together with an established mechanism of action and well characterized safety profile."

The NDA is supported by data from the Phase 3 program which was presented at PAINWeek 2025. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820).

Both Phase 3 trials evaluated the efficacy and safety of fast-acting meloxicam versus placebo and included an opioid arm (tramadol 50mg q6h) to confirm the sensitivity of the pain model. The primary endpoint in both trials was defined by the Sum of Pain Intensity Difference (SPID) based on the Numeric Rating Scale measured over 0-48 hours (SPID0-48h) versus placebo. Both trials evaluated the reduction in opioid usage that was defined by number of mean doses of opioid rescue medication and proportion of opioid-free patients over the combined in- and out-patient treatment phases. In both studies, fast-acting meloxicam met primary and secondary endpoints and demonstrated a safety profile consistent with the well-characterized safety profile of this mechanism of action.

Viatris is pursuing several value-added medicines, including fast-acting meloxicam, to drive high value products through life cycle optimization including new formulations, delivery technologies and indications.

Phase 3 Trial Design for Herniorrhaphy (NCT06215859) and Bunionectomy (NCT06215820) 
Post-operative herniorrhaphy and bunionectomy patients aged 18 or older who experienced moderate-to-severe acute pain following surgery were eligible to participate in the trials, NCT06215859 and NCT06215820, respectively. 579 herniorrhaphy subjects and 410 bunionectomy subjects were randomized and received doses of either MR-107A-02, tramadol or placebo during the inpatient phase (0-48h). During the outpatient phase, subjects continued to receive the study drug. Subjects randomized to receive tramadol during the inpatient phase received placebo in the outpatient phase.

About Acute Pain
Acute pain is defined as pain of sudden onset associated with a known cause—such as surgery, trauma, or acute illness—and is typically self-limiting, resolving within 30 days to three months. It affects more than 80 million individuals in the United States. each year and is a primary driver of emergency department visits and postoperative morbidity. Clinically, it contributes to delayed recovery, impaired physical function, poor sleep, and reduced quality of life. Economically, the burden of acute pain is substantial, including both direct medical expenses and indirect costs such as lost productivity and disability. Societally, inadequate pain control affects patient satisfaction and rehabilitation outcomes, contributes to opioid prescribing and potential misuse. Despite the widespread impact, more than half of surgical patients report inadequate pain relief, reflecting a significant unmet need for effective, non-opioid treatment options with rapid onset and favorable safety profiles.

About Fast-Acting Meloxicam
Fast-acting meloxicam (MR-107A-02) is an investigational, novel fast-acting oral formulation of meloxicam being developed by Viatris for the treatment of moderate-to-severe acute pain. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID), and this formulation was designed to enable more rapid dissolution and absorption than currently approved oral meloxicam products. Viatris has reported positive results from two pivotal Phase 3 studies of MR-107A-02 in acute post-surgical pain models following bunionectomy and herniorrhaphy. MR-107A-02 has been submitted to the U.S. Food and Drug Administration for review under the 505(b)(2) regulatory pathway and has not been approved by any regulatory authority.

References

Lopez et al. "A real-world database analysis of the prevalence of pain medication use in the United States." Pain Reports, vol. 11, 2026, e1396. Centers for Disease Control and Prevention. About Prescription Opioids. Accessed April 2026. About Viatris 
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.

Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that FDA has accepted for review the NDA for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain; the FDA has assigned a PDUFA goal date of Dec. 27, 2026; FDA's acceptance of the NDA for investigational fast-acting meloxicam takes us one step closer to bringing a potential non-opioid first-line treatment option to patients with moderate-to-severe acute pain, which will help address an important public health need in the United States; fast-acting meloxicam is one of several value-added medicines in our pipeline; we are proud of the strength of the clinical profile supporting this program, which includes a fast speed of onset of action, strong and sustained analgesic efficacy with a significant reduction in opioid usage, together with an established mechanism of action and well characterized safety profile; information about clinical trials; in both studies, fast-acting meloxicam met primary and secondary endpoints and demonstrated a safety profile consistent with the well-characterized safety profile of this mechanism of action; Viatris is pursuing several value-added medicines, including fast-acting meloxicam, to drive high value products through life cycle optimization including new formulations, delivery technologies and indications. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.

SOURCE Viatris Inc.

VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Viatris (VTRS - Free Report) Viatris, a global healthcare company, was formed in November 2020 through the merger of the erstwhile Mylan and Pfizer’s Upjohn businesses. The company has operations in over 165 countries. Viatris’ portfolio consists of generics (including complex products), globally recognized iconic brands and an expanding portfolio of innovative drugs. 

VTRS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 6.3; value investors should take notice.

For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $2.47 per share. VTRS boasts an average earnings surprise of +10%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, VTRS should be on investors' short list.

On May 28, 2026, we conducted a discounted cash flow (DCF) analysis for Canadian National Railway Co (CNI), which has shown a positive price performance recentl

MONTRÉAL, 28 mai 2026 (GLOBE NEWSWIRE) -- Le CN (TSX: CNR) (NYSE: CNI) salue la décision du Surface Transportation Board (STB) de suspendre l'examen de la fusion et d'ordonner à Union Pacific (UP) et à Norfolk Southern (NS) de fournir d'importants renseignements supplémentaires.

CN (CNI) reported earnings 30 days ago. What's next for the stock?

MONTREAL, June 03, 2026 (GLOBE NEWSWIRE) -- Janet Drysdale, Executive Vice-President and Chief Commercial Officer and Patrick Whitehead, Executive Vice-President and Chief Operating Officer of CN (TSX: CNR) (NYSE: CNI), will address the Wells Fargo 16th Annual Industrials and Materials Conference on June 11, 2026, at 9:45 a.m. Eastern Time (ET).

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that propane export shipments from South Beamer, Alberta to Watson Island, British Columbia reached an all-time monthly record for the corridor in May, while staying within the existing commercial arrangements. The achievement represents an increase in carloads of 40% compared to May 2025 and beating CN's previous monthly record from August 2024, reflecting continued operational improvements across the supply chain.

BHP inks rail deals with CNI and CP, giving the Jansen potash project dual access to Vancouver's Westshore as first production nears.

Key Takeaways CNI secured a transport agreement with BHP for the Jansen Potash Mine in Saskatchewan. Canadian National Railway will move potash to Canada's West Coast export terminals. CNI could benefit from higher shipment volumes and a stronger bulk commodity business. Canadian National Railway (CNI - Free Report) strengthened its long-term growth prospects by securing a transportation agreement with BHP for the Jansen Potash Mine, one of the world's largest new potash developments. The agreement positions CNI to transport potash from Saskatchewan to export terminals on Canada's West Coast, creating a new avenue for freight growth and reinforcing its role in supporting Canada's resource economy.

The deal highlights the strategic advantage of CNI's extensive rail network, which efficiently connects resource-producing regions with key export gateways. As production at the Jansen mine ramps up, CNI stands to benefit from higher shipment volumes, improved network utilization and increased participation in the growing potash export market. The agreement also strengthens the company's bulk commodity franchise, a key contributor to its overall revenue base.

Potash remains a critical component of global fertilizer production, and rising demand for agricultural products should support long-term growth in fertilizer exports. By partnering with BHP on this landmark project, CNI positions itself to capitalize on durable agricultural and commodity demand trends while deepening its relationship with a major global mining company.

Overall, the agreement reflects CNI's ability to secure strategic, long-duration transportation contracts that support future volume growth. As the Jansen project advances toward full production, CNI could benefit from sustained freight demand, enhancing revenue visibility and strengthening its position as a leading North American rail transportation provider.

CNI’s Share Price PerformanceCNI’s shares have gained 23.2% in the past six months compared with the Transportation - Rail industry’s 20% growth.

Image Source: Zacks Investment Research

CNI’s Zacks RankCNI currently carries a Zacks Rank #3 (Hold).

Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider Expeditors International of Washington, Inc. (EXPD - Free Report) and International Seaways (INSW - Free Report) . 

EXPD currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Expeditors has an expected earnings growth rate of 11.9% for the current year.  The company has an encouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 13.96%.

INSW currently sports a Zacks Rank #1.

INSW has an expected earnings growth rate of more than 100% for the current year. The company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 33.93%.

Here we pick two railroad stocks, UNP and CNI, which have a solid five-year dividend growth history.

On April 27, 2026, Crown Castle Inc (CCI) shares fell 3.4% to $83.44. Over the past year, the stock has experienced significant volatility, trading between a 52

Most REITs are not ideal “forever” holdings. A few REITs have rare long-term compounding potential. Three unique landlords could keep growing for decades.

On June 04, 2026, Crown Castle Inc CCI shares rose 5.8% to a current price of $93.79. The stock has shown a 52-week range of $75.96 to $115.76, indicating significant volatility over the past year. The recent price increase reflects a positive sentiment in the market, despite the stock's overall performance being slightly negative year-over-year.

GF Value™ verdict: CCI is currently priced at $93.79, which is 4.3% above its GF Value™ estimate of $89.90.GF Score™: 62/100, indicating an above-average ranking based on key performance metrics.Most notable signal: Insiders have bought $0.1M worth of shares in the last three months, signaling confidence in the company's future. Is CCI Overvalued or Undervalued? According to the GF Value™, Crown Castle Inc is currently overvalued. The stock's price of $93.79 exceeds the GF Value™ estimate of $89.90 by 4.3%. This indicates a lack of margin of safety for prospective investors, as the stock is trading above its intrinsic value. The GF Valuation label classifies the stock as “Fairly Valued,” suggesting that while it is not severely overvalued, there are risks associated with its current price level. Investors should consider the potential for price corrections or stagnation in growth as the market adjusts to the valuation metrics.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current price in relation to the GF Value™, it is important for investors to weigh the risks of entering a position at this valuation against the potential for future growth.

How Does CCI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 38.8x 37.8x Forward P/E 42.2x N/A The current P/E ratio of 38.8x is 3% above its 5-year median P/E of 37.8x. Additionally, the forward P/E of 42.2x indicates that analysts expect earnings growth; however, this level also suggests that the stock is trading at a premium compared to its historical valuation metrics. This P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that CCI is presently overvalued.

What Does CCI's GF Score™ Tell Us? Metric Rating GF Score™ 62 Financial Strength 2/10 Profitability 7/10 Growth 1/10 Valuation 9/10 Momentum 5/10 The GF Score™ of 62/100 indicates that Crown Castle Inc is positioned above average in terms of potential long-term returns. However, the company exhibits weaknesses in Financial Strength and Growth, with ratings of 2/10 and 1/10 respectively. On the other hand, it shows strong profitability with a rating of 7/10 and a robust Valuation score of 9/10. This mixed performance suggests that while CCI has favorable valuation metrics, its financial stability and growth prospects may raise concerns for long-term investors.

What Are Insiders Doing with CCI Stock? In recent months, insider activity has shown a positive trend as insiders have purchased $0.1 million worth of Crown Castle Inc shares without any selling activity reported. This pattern of buying can often be interpreted as a signal of confidence from those with intimate knowledge of the company’s operations and prospects. Such insider purchases may indicate that they believe the stock is undervalued at current levels and expect future price appreciation.

What This Means for Investors Based on the GF Value™ assessment, Crown Castle Inc is currently overvalued. With its price exceeding the intrinsic value estimate by 4.3%, potential investors should approach with caution, considering both the market's sentiment and the company's financial standing.

For the complete analysis, visit the Crown Castle Inc CCI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CCI's GF Score™?

CCI's GF Score™ is 62/100, indicating an above-average ranking based on financial strength, profitability, growth, valuation, and momentum, which suggests it may generate higher long-term returns.

Is CCI overvalued or undervalued?

CCI is currently overvalued according to the GF Value™, with its price of $93.79 exceeding the GF Value™ estimate of $89.90 by 4.3%.

What is CCI's P/E ratio?

CCI's P/E (TTM) ratio is 38.8x, which is 3% above its 5-year median P/E of 37.8x, suggesting that the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Toronto, Ontario--(Newsfile Corp. - June 10, 2026) - Canadian Copper Inc. (CSE: CCI) ("Canadian Copper" or the "Company") today announced that a court hearing in Vancouver, Canada is scheduled on June 29th, 2026, at 10AM (PST) to approve the Caribou Complex transaction. Next Steps After Court Hearing The Company, as buyer, and FTI Consulting Canada Inc. the court appointed Receiver of Trevali Mining New Brunswick Ltd.

Coupang, Inc. (CPNG - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this company have returned -20% over the past month versus the Zacks S&P 500 composite's +8.8% change. The Zacks Internet - Commerce industry, to which Coupang belongs, has gained 9.7% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Coupang is expected to post a loss of $0.14 per share for the current quarter, representing a year-over-year change of -800%. Over the last 30 days, the Zacks Consensus Estimate has changed -400%.

For the current fiscal year, the consensus earnings estimate of -$0.17 points to a change of -241.7% from the prior year. Over the last 30 days, this estimate has changed -15.9%.

For the next fiscal year, the consensus earnings estimate of $0.4 indicates a change of +336.8% from what Coupang is expected to report a year ago. Over the past month, the estimate has changed -33.3%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Coupang is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Coupang, the consensus sales estimate for the current quarter of $8.93 billion indicates a year-over-year change of +4.8%. For the current and next fiscal years, $37.75 billion and $42.7 billion estimates indicate +9.3% and +13.1% changes, respectively.

Last Reported Results and Surprise HistoryCoupang reported revenues of $8.5 billion in the last reported quarter, representing a year-over-year change of +7.5%. EPS of -$0.15 for the same period compares with $0.06 a year ago.

Compared to the Zacks Consensus Estimate of $8.57 billion, the reported revenues represent a surprise of -0.72%. The EPS surprise was +74.58%.

Over the last four quarters, Coupang surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Coupang is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Coupang. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Coupang, Inc. (CPNG - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this company have returned -21.4% over the past month versus the Zacks S&P 500 composite's +4.8% change. The Zacks Internet - Commerce industry, to which Coupang belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Coupang is expected to post a loss of $0.14 per share, indicating a change of -800% from the year-ago quarter. The Zacks Consensus Estimate has changed -640% over the last 30 days.

The consensus earnings estimate of -$0.17 for the current fiscal year indicates a year-over-year change of -241.7%. This estimate has changed -13.3% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $0.4 indicates a change of +336.8% from what Coupang is expected to report a year ago. Over the past month, the estimate has changed -31%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Coupang.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Coupang, the consensus sales estimate for the current quarter of $8.93 billion indicates a year-over-year change of +4.8%. For the current and next fiscal years, $37.75 billion and $42.7 billion estimates indicate +9.3% and +13.1% changes, respectively.

Last Reported Results and Surprise HistoryCoupang reported revenues of $8.5 billion in the last reported quarter, representing a year-over-year change of +7.5%. EPS of -$0.15 for the same period compares with $0.06 a year ago.

Compared to the Zacks Consensus Estimate of $8.57 billion, the reported revenues represent a surprise of -0.72%. The EPS surprise was +74.58%.

Over the last four quarters, Coupang surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Coupang is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Coupang. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

It can be frustrating to watch a stock you own flounder while the rest of the market seems to climb to new heights every day. But if the business is continually growing in value, patience will eventually be rewarded for those who hold it over the long term.

This describes Coupang (CPNG 2.29%) perfectly. The stock is down 67% from its initial public offering (IPO) a little over five years ago and has suffered further pain in recent months due to a data leak scandal. At the same time, revenue is up close to 200% cumulatively since its IPO.

A combination like this makes Coupang a once-in-a-decade buying opportunity. Here's why investors should consider adding the stock to their portfolios today.

Today's Change

(

-2.29

%) $

-0.40

Current Price

$

16.86

The other side of a data leak scandal Coupang sold stock in its 2021 IPO at $35 a share and then saw it jump to $63.50 on its first day of trading. It then fell to just above $10 in the 2022 bear market. All the while, revenue for its e-commerce and online subscription ecosystem kept compounding to new heights.

The stock had been recovering over the last few years and peaked above $30 in late 2025. But then a new headwind emerged: a data leak scandal in late 2025. Coupang's customer data was leaked by a rogue former employee, leading to outrage in South Korea that spilled over into the government's trade negotiations with the United States.

A small boycott of Coupang's platform led to a slight deceleration in active customers from Q4 2025 to Q1 2026. On the Q1 conference call, management said it had already recovered 80% of these lost customers by the end of April, meaning this was barely a two-quarter speed bump. Total revenue grew 8% year over year last quarter to $8.5 billion, with an expectation for acceleration later this year once the data leak scandal is fully over.

Coupang stock remains down around 50% from its 2025 high, sitting at about $16.50 today.

Image source: Getty Images.

Replicating the business worldwide South Korea should remain a solid growth driver for Coupang. It doesn't hurt that the country's economy is booming because of its specialty in memory chips for the artificial intelligence (AI) revolution. Expect durable double-digit growth from continued e-commerce expansion in the region.

More explosive growth may come from its new expansion into Taiwan. The country has a population of 23 million, is wealthy, and also serves as a hub for AI chip production. Coupang's new business in Taiwan is at a "hypergrowth rate," according to management on the conference call, but it is currently losing a lot of money. Over the next few years, this segment should continue to scale and eventually generate billions, if not over $10 billion, in revenue for Coupang.

CPNG EBIT Margin (TTM) data by YCharts

Why Coupang stock is incredibly cheap The steady growth of Coupang's South Korean e-commerce marketplace and the rapid expansion in Taiwan should assure double-digit revenue growth in the years ahead, not to mention its ancillary businesses, such as food delivery, rapid delivery, financial technology services, and a new intelligent cloud business. These rising tides can grow Coupang's revenue from $35 billion over the last 12 months to $70 billion in five years.

A larger question is what profit margins will be five years from now. Coupang operates today at close to breakeven, making it difficult to value on a price-to-earnings ratio (P/E) basis. What we do know is that the core South Korean e-commerce segment had an EBITDA (earnings before interest, taxes, depreciation, and amortization) of 5%, with Q4 coming in at 7.7% before the data leak scandal.

This indicates the potential for significant consolidated operating leverage in the years ahead as new projects, such as Taiwan, begin to mature. If Coupang can grow its revenue to $70 billion with a 10% profit margin, that is $7 billion in annual earnings power.

Coupang's market value today is just under $30 billion. For investors with the patience to hold for five years, Coupang looks like a bargain stock trading at under 5x forward earnings based on these growth assumptions.

Sitting here today, with stocks like Micron Technology zooming past a $1 trillion market cap and delivering 10x gains in a year, can make you feel like there is no opportunity left to buy artificial intelligence (AI) stocks. Stocks like Nvidia have been soaring for the last few years, and now trade at premium valuations with major downside risks if the AI spending boom peters out.

What if I told you there were still cheap AI stocks to buy? You just have to look abroad in order to find them. Here's why Coupang (CPNG 2.29%) is the one AI stock you can buy right now if you missed out on Nvidia, Micron, and other winners of the last few years.

Today's Change

(

-2.29

%) $

-0.40

Current Price

$

16.86

AI tech company in South Korea Coupang's main business is an e-commerce marketplace, built in a similar manner to Amazon. Unlike the mainline AI companies in Silicon Valley, Coupang is using AI from a robotics and automation perspective across its vast network of warehouses in South Korea. It wants to maximize the use of robots in its warehouses to save time and money and deliver items to customers faster.

Outside of e-commerce, Coupang utilizes AI within its advertising, financial technology, and food delivery divisions. It wants to use automation to improve the customer journey while simultaneously maximizing profits. AI is more than the chatbots popular with consumers today.

In a more direct investment, Coupang recently launched what it calls the Coupang Intelligent Cloud (CIC), which is building AI data centers for itself and, potentially, third-party customers. Sitting less than a year after the announcement, it is unclear exactly how ambitious Coupang plans to invest in its AI cloud, but it shows how laser-focused the technology company is on layering in AI into its business.

Image source: Getty Images.

Huge economic growth opportunity There are 24 million active Coupang customers, which is close to half the population of South Korea. They flock to the service because of its rapid delivery and wide product selection at low prices. Over the last 12 months, the business has generated $35 billion in revenue, primarily from its e-commerce platform in South Korea.

We may see a catalyst in consumer retail spending in South Korea, and it is entirely related to the AI boom. Supply shortages for memory chips are driving up prices, which greatly benefits South Korean semiconductor giants Samsung and SK Hynix. Because of this massive profit boost, the two companies are paying bonuses to employees that could total $40 billion combined in 2026. With total national income at $1 trillion, this is a 4% increase that goes straight to customer wallets to spend on discretionary items, hopefully on Coupang.

Over the long term, greater spending on e-commerce than on in-person shopping should drive growth for Coupang and its expansion into other categories, such as food delivery. It has also made an aggressive expansion play into Taiwan, where revenue is growing by more than 100% year over year -- albeit from a small base -- according to management.

CPNG Revenue (TTM) data by YCharts

Why Coupang stock is a fantastic buy today A lot of moving parts could impact Coupang's profitability in the near term. It may get a boost from this South Korean memory chip boom, while headwinds to profits may arise from rising losses from its expansion into Taiwan.

What matters is the customer loyalty being built through Coupang's superior service offering, leading to durable revenue growth and long-term operating leverage. Right now, Coupang has a market cap of only $29.55 billion and revenue of $35 billion. Revenue should grow durably, driven by multiple tailwinds. Assuming a 12% revenue growth rate, Coupang's revenue will have close to doubled to $61.7 billion five years from now.

A measly 10% profit margin on this $61.7 billion in revenue is $6.2 billion in earnings, or less than 5 times its current market value. This makes Coupang stock incredibly cheap. Stay patient, Coupang can be the tech stock that delivers massive gains in your portfolio over the next five years, just as Nvidia has for the last five.

Coupang, Inc., a U.S.-based technology leader, today was named to the Fortune 500® for the fourth consecutive year, jumping 10 places to No. 132 as it continues to grow and advance its innovative global fulfillment and logistics network. The Fortune 500® ranks the largest U.S. companies by total revenue each year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603035002/en/

Coupang climbs 10 spots on the Fortune 500 to No. 132

Seattle-based Coupang generated $34.5 billion in revenue in 2025, an increase of 14% over the prior year, powered by its focus on innovation, customer service and expansion in new markets.

Coupang has set a new standard for speed and quality in online services, applying artificial intelligence across its operations to help businesses, including in the U.S., reach new international customers. Coupang has operations and support services in geographies including the U.S., Korea, Taiwan, Singapore, China, India, Japan and across Europe. Its reach spans more than 190 countries and territories, connecting tens of millions of customers to quality products.

Enabling cross-border commerce at scale

“As a U.S. technology company, Coupang is redefining global commerce and driving economic expansion by bridging the gap between businesses and customers worldwide,” said Robert Porter, Coupang chief global affairs officer. “Last year, our strategic investments in advanced AI, custom robotics and cutting-edge logistics drove over $5 billion in exports of U.S. goods and services. Building on this momentum, we will continue to seek to create unprecedented opportunities for businesses across the United States, Korea, Taiwan and Japan, and for customers in all 190 markets we serve.”

Coupang provides end-to-end logistics solutions that help businesses grow in new markets. The company works with businesses from cherry farmers in the U.S. to olive oil artisans in Italy and skilled textile crafters in Japan to sell to new customers outside their home countries. Coupang supports their growth through a range of turn-key services to help them compete and thrive, including fulfillment and logistics solutions, marketing, customer service and export assistance to connect their products to global customers.

In 2025, Coupang enabled the sale of billions of dollars' worth of goods and services from U.S. businesses to international markets. In South Korea, small business sellers on Coupang grew their sales by 21% in 2025, more than 100 times the national small business growth rate.

Coupang also connects global luxury brands with customers worldwide through Farfetch. With more than 1,400 brands, boutiques and department stores, Farfetch serves customers in 190 countries and territories with the United States as its largest market, accounting for millions of customers.

Driving rapid growth in Taiwan

Coupang is accelerating its growth and investment in Taiwan. The company opened its fourth smart fulfillment and logistics center in Taiwan in 2026, expanding the company’s advanced global logistics network in the country. This technology powers Rocket Delivery, which now reaches across approximately 70% of Taiwan’s geography, providing next-day delivery seven days a week. Coupang has invested in Taiwan across multiple phases, including the largest approved U.S. investment in Taiwan last year and the second-largest approved foreign investment overall.

Technology driving global commerce

Coupang has invested billions of dollars in artificial intelligence, robotics and cloud computing to support the growth of its global operations. Its logistics network uses AI to forecast demand, streamline fulfillment and optimize delivery across regions. These systems are powered by Coupang Intelligent Cloud, enabling scalable AI training and real-time data processing. Since its founding in 2010, Coupang has developed an integrated technology and logistics ecosystem designed to deliver fast, reliable service across diverse markets.

Recognized for innovation and impact

Coupang’s innovation continues to receive international recognition. In 2026, it was named to the LexisNexis Top 100 Global Innovators list for the second consecutive year. The company also ranked No. 2 in Fast Company’s 2025 list of the World’s Most Innovative Companies in the Retail category.

About Coupang

Coupang is a technology and Fortune 150 company listed on the New York Stock Exchange (NYSE: CPNG). It provides retail, restaurant delivery, video streaming, and fintech services globally through brands including Coupang, Eats, Play, Rocket Now, and Farfetch.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260603035002/en/

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Coupang, Inc. (CPNG - Free Report) .

Coupang currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.97 approximates between Strong Buy and Buy.

Of the 15 recommendations that derive the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 53.3% and 6.7% of all recommendations.

Brokerage Recommendation Trends for CPNG

Check price target & stock forecast for Coupang here>>>

While the ABR calls for buying Coupang, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in CPNG?In terms of earnings estimate revisions for Coupang, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$0.17.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Coupang. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Coupang.

SummaryCompaniesRegulator says Coupang's lack of safety measures led to data breachPenalty amounts to 1.4% of Coupang's revenue in 2025Coupang apologises for concern it caused customers and the publicSEOUL, June 11 (Reuters) - South ​Korea will fine e-commerce giant Coupang (CPNG.N), opens new tab 625 billion won ($409.30 million) over a massive leak of ‌customer information last year and illegal collection of personal information, in the country's largest data breach penalty on a company.

The Personal Information Protection Commission said the New York-listed company had leaked personal data of more than 33 million customers and failed to detect the breach within ​the 72 hours required by the law.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The fine amounts to 1.4% of Coupang's revenue of 45 trillion ​won in 2025, according to Reuters' calculation.

"This accident occurred due to Coupang's lack of safety ⁠measures and systems, not sophisticated hacking," Song Kyung-hee, the chairperson of the privacy regulator, told a briefing on Thursday.

After ​the fine was announced, Coupang apologised for having caused concern to the public and its customers.

However, the company said ​that "we regret that our proactive measures to prevent secondary harm from last year's data leak incident, as well as our explanations based on clear facts, were not sufficiently reflected" in the regulator's decision.

Seattle-based Coupang generates most of its revenue in South Korea, offering fast ​delivery of groceries, food and other goods.

The penalty followed a finding by a government-led investigation earlier this year that blamed ​the breach on management failure.

Coupang logo is seen in this illustration taken February 11, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

South Korea's science ministry at the time said that a former employee, who was a Chinese national, ‌stole a ⁠security key and gained unauthorised access to customer accounts.

Song said Coupang's security system allowed a hacker to easily access the personal information of all of its customers, even after the suspect left the company.

The firm also failed to detect an unusual increase in traffic to its customer data until it was alerted by a customer's inquiry, she added.

Separately, ​the regulator found the company's ​marketing program illegally collected ⁠information on online activities of around 11 million customers without their agreement, Song said.

Probes into the data breach added to trade friction with Washington amid concerns Korean authorities had gone ​too far in their treatment of the U.S.-listed company, while the allies have ​been negotiating details ⁠on a trade deal struck last year.

South Korea said, however, its Coupang probe was neither a trade nor security issue and should be handled separately from the ongoing talks with Washington.

The firm is estimated to control about 40% of South Korea's logistics ⁠services, the ​largest market share among peers, according to Seoul-based IM Securities.

"Coupang has grown ​its e-commerce service significantly based on vast customer data," Song said. "But the company did not have a system to protect and manage customer ​information despite its business scale."

($1 = 1,527.0000 won)

Reporting by Heejin Kim and Joyce Lee; Editing by Himani Sarkar and Sonali Paul

Our Standards: The Thomson Reuters Trust Principles., opens new tab

South Korean authorities have imposed a record-breaking fine of $624 billion won (over $400 million) on retail giant Coupang after a data breach last year compromised the personal data of more than 34 million customers.

Seoul’s Personal Information Protection Commission issued the maximum penalty on Thursday following discovery of the breach in December 2025. The retail giant, which is headquartered in the U.S. but popular in South Korea and likened to the “Amazon of Asia,” had said the months-long data breach allowed a former employee to obtain names, email and shipping addresses, phone numbers, and order histories of about two-thirds of South Korea’s population.

Coupang told BBC News that it plans to challenge the regulator’s decision. The fine represents a rare case of a financial penalty issued against a U.S.-based firm. Korean lawmakers have accused some of their American counterparts of imposing political pressure after reports that U.S. representatives were linking the data breach with U.S.-South Korean bilateral ties in response to the case against Coupang’s executives.

U.S. companies rarely face financial sanctions or criminal prosecution for data breaches as a result of lacking laws and enforcement powers.